ARE — Q2 2026 Financial Report Analysis

Occupancy losses, not rent cuts, drove a 26% fall in core FFO — while $222 million of write-downs marked the exit price on non-core assets

Alexandria Real Estate Equities (NYSE: ARE) is a REIT — a landlord company that owns income-producing property and passes most of its taxable income to shareholders as dividends — specializing in laboratory and life-science campuses, concentrated in Greater Boston, San Diego and the San Francisco Bay Area. Its second quarter of 2026, reported in the 10-Q filed August 3, 2026, was defined by a single mechanical problem: space that emptied out faster than it was refilled.

Total revenue fell 13.0% to $662.8 million. Funds from operations per share, as adjusted — FFO is the REIT industry's cash-earnings measure, net income with real-estate depreciation added back because buildings do not actually wear out on an accounting schedule; "as adjusted" further strips out impairments and investment gains — fell 25.8% to $1.73 from $2.33. The GAAP net loss attributable to common stockholders actually narrowed, to $73.7 million (-$0.43 per share) from $109.6 million (-$0.64), but for reasons that have nothing to do with the buildings: a $163.8 million swing in investment income (a $133.2 million gain this quarter against a $30.6 million loss last year, almost entirely unrealized marks on ARE's venture stakes) plus $41.7 million less depreciation more than offset $92.9 million of additional real-estate impairments. The headline loss and the underlying operating trend point in opposite directions this quarter.

Metrics

Two rows deserve unpacking before anything else.

The two FFO lines move in opposite directions. Nareit-defined FFO per share rose 26.4% to $2.44 purely because that definition adds back real-estate impairments — $1.30 per share of them this quarter versus $0.77 a year ago. FFO as adjusted, which removes impairments and the unrealized investment swings, is the line that tracks the business: down 25.8%. Anyone quoting the +26% number is quoting an accounting artifact of a bad quarter, not a good one.

Same-property NOI compares only the 289 properties owned across both periods, stripping out acquisitions, disposals and newly delivered buildings — it is the cleanest read on the existing portfolio. It fell 10.6% ($46.9 million). Management attributes the decline to occupancy, not pricing: "previously disclosed key lease expirations with expected downtime aggregating 657,492 RSF during the three months ended March 31, 2026 and 260,888 RSF during the three months ended June 30, 2026." Same-property rental revenue fell $42.2 million (8.9%) on that occupancy drop, and tenant recoveries fell a further $17.9 million (10.8%) — with 91% of leases triple-net (tenants reimburse taxes, insurance and operating costs), empty space stops reimbursing, so vacancy hits the expense-recovery line roughly as hard as the rent line.

The demand backdrop management now quantifies

The filing's "Trends that may affect our future results" section is unusually blunt about the market, and the figures matter more than the narrative: life-science space availability in ARE's top three markets "rose to approximately 29% during 2025, from approximately 4% in 2021," while average tenant space requirements "declined by more than 60% in 2025 compared to 2021." That is a demand-supply scissors, not a cyclical dip. Management lists the 2025-into-2026 aggravators specifically — leadership turnover at HHS, FDA and NIH, threatened cuts to NIH research funding and to indirect-cost reimbursement, drug-pricing scrutiny, tariffs — and notes a fifth consecutive year of the biotech bear market, with life-science venture fundraising at its lowest since 2016. The one qualification offered: the biotech IPO window "began to reopen selectively in 2026," though "the recovery remained uneven."

Against that backdrop ARE's 86.9% occupancy is a relative outcome, not an absolute one — the filing claims it "outperforms market occupancy levels in our top three markets." The internal trend is still down: Greater Boston 83.0% (from 90.1% a year ago), San Francisco Bay Area 83.1% (from 88.9%), San Diego 89.9% (from 94.8%).

Leasing: the first genuinely encouraging datapoint in several quarters

Q2 leasing volume exceeded 1.0 million RSF (rentable square feet), up 60% from Q1's 647,356 RSF and about 87,000 RSF above the trailing four-quarter average of 952,365 RSF. Crucially, the pricing on renewals improved sharply: rental rate changes on renewed and re-leased space were -0.7% on a GAAP basis and -4.3% cash, versus -15.0% and -15.8% in Q1. Two consecutive datapoints do not make a trend, and the 1H26 blended figure is still -7.4%, but Q2 rents on rollover were close to flat — the filing's own full-year guidance still assumes -9.0% to -1.0% GAAP, so Q2 landed at the favorable end of what management expects for the year.

There is also 1.4 million RSF (4.0% of operating square footage) already leased but not yet occupied, worth roughly $69 million of annual rental revenue, with a weighted-average expected occupancy date around November 2026 and 64% of it expected in place by year-end. Including that signed-not-occupied backlog, occupancy is 90.9% rather than 86.9%. That backlog is the single most important support under the second-half numbers.

The offset: another 451,450 RSF of known 2026 expirations with a weighted-average expiry of August 2026, plus 1.4 million RSF identified in 2027, both carrying expected downtime of "approximately 12 to 24 months on a weighted-average basis." The vacancy drag is not finished.

Impairments: the market is pricing ARE's non-core assets, and the marks keep coming

Real-estate impairments — write-downs recognized when a property's carrying value on the books exceeds what it can realistically be sold for — totaled $222.5 million in the quarter and $228.0 million for the first half. The named components are almost all assets being exited rather than operated:

• $64.2 million on a 425,000 SF land parcel in Sorrento Mesa, San Diego, written down to roughly $43.1 million; expected to be sold to a residential developer.
• $61.6 million on a 247,743 RSF non-laboratory property in Canada, written down to about $42.4 million, plus a further $27.8 million on the Montreal portfolio after a sales-agreement amendment (carrying value now ~$134.5 million). ARE is exiting Canada; ~$33.0 million of cumulative currency translation losses sit in other comprehensive income awaiting reclassification to earnings on completion.
• $29.3 million additional on a 1.1 million SF SoMa (San Francisco) development site, "based on recent negotiations with a potential buyer," on top of $333.4 million written off in December 2025 — the site is now carried at roughly $41.3 million.
• $24.8 million additional on a vacant Cambridge office building, now carried at ~$43.7 million, following $105.7 million taken in December 2025.
• $28.2 million across five mostly non-laboratory San Diego properties and a land parcel.
• Partially offset by a $23.3 million reversal in Palo Alto, where a purchase and sale agreement at $163.0 million came in above the December 2025 marked-down carrying value. That sale closed in July 2026 with no gain or loss.

The pattern in the repeat write-downs is the informative part: on both the SoMa site and the Cambridge building, the second mark was set by actual buyer negotiations and came in below the December 2025 estimate. Book values on the exit list are still catching down to bids. Cumulative context from the filing's own table: $223.1 million of impairments in 2024, $2.20 billion in 2025, $228.0 million in 1H26.

Balance sheet: the gap between where leverage is and where it needs to be

Net debt and preferred stock to Adjusted EBITDA stood at 7.0x (Q2 annualized) against a fourth-quarter 2026 target of 5.6x–6.2x, with fixed-charge coverage at 3.3x versus a 3.6x–4.1x target. Closing that gap in two quarters depends entirely on selling assets: the 2026 plan calls for $2.90 billion of dispositions, sales of partial interests and other capital sources at the midpoint, of which only $170 million has actually closed as of the filing date. Another $1.16 billion is under non-refundable deposit, signed LOI or purchase-agreement negotiation (together 46% of the target), $1.10 billion is "in process," and $471 million represents "multiple alternatives under evaluation."

Timing has already slipped once: the weighted-average projected completion date of those transactions moved roughly six weeks, from August to September 2026, which is why full-year interest expense guidance rose $20 million to $260–$300 million. That is the specific mechanism to watch — every further slip converts directly into interest expense, because the commercial paper program is carrying the bridge ($1.99 billion outstanding at quarter-end, at a 4.17% weighted-average yield on 15-day paper).

What is not a problem: maturity structure and liquidity. Only 6% of total debt matures through 2028, the weighted-average remaining debt term is 9.7 years (longest among S&P 500 REITs per the filing), liquidity is $3.60 billion, and the $5.0 billion credit line has been extended to January 2032 with the spread cut to SOFR + 0.725% from SOFR + 0.835% (a ~$3.3 million write-off of unamortized fees will hit Q3). The $500 million buyback authorization remains entirely unused.

The year-to-date GAAP profit of $286.7 million ($1.68 per share) is worth flagging as non-recurring: it exists because February 2026 tender offers repurchased $1.33 billion of principal across the 2050, 2051 and 2052 notes for $952.2 million cash, producing a $366.4 million gain on early extinguishment of debt — $2.14 per share, and excluded from adjusted FFO. Buying back long-dated low-coupon paper at a deep discount is real economic value, but it is a one-time balance-sheet action, not earnings power.

Development: spending down, and a pivot away from lab

One project was delivered in Q2 — 426,927 RSF at 4135 Campus Point Court, 100% occupied by Bristol Myers Squibb, adding $57 million of incremental annual NOI. A further $42 million is expected from deliveries in 2H26 and $93 million from 2027–2028 projects (1.26 million RSF, 68% leased or negotiating), for $135 million of total future incremental annual NOI from the active pipeline, which is 71% leased or under negotiation. An additional $40 million of cash NOI arrives simply from free-rent periods burning off over roughly the next five months.

The more strategically interesting move is the retreat from lab-only use. At 3000 Minuteman Road in Greater Boston, a 159,947 RSF lease with an "advanced technology tenant" let ARE pivot part of a redevelopment away from laboratory/biomanufacturing to a lower-cost use, cutting that project's budget by about $80 million; the space returned to the operating pool (costing 40 bps of reported occupancy until it delivers in Q2 2027). LOIs for another 108,800 RSF of advanced-technology use are signed at 311 Arsenal Street. Five projects totaling 1.4 million RSF, only 15% leased or negotiating, remain under review for continuation, repositioning, pausing or sale. Preliminary 2027 construction spending is now guided to $1.15–$1.65 billion, down $100–$600 million from the 2026 midpoint of $1.75 billion.

Converting lab shells to non-lab tenants is capital-light relative to finishing them as labs, but it also means accepting rents below the lab-space underwriting those sites were bought and started on.

Dividend

The declared dividend was $0.72 per share, unchanged from Q1 but 45.5% below the $1.32 declared in Q2 2025 — the single largest year-over-year change in the release. At the reset level the payout ratio is 42% of adjusted FFO, a 5.4% yield on the quarter-end price, with coverage of roughly 2.4x. Post-cut, the dividend is well covered even if adjusted FFO keeps sliding; management frames the retained cash as funding for reinvestment and debt reduction, and $2.60 billion of operating cash flow has been retained across 2022–2026 guidance midpoint.

Takeaway: ARE's second quarter is a bridge-timing story, not a rent story — Q2 rollover rents were nearly flat (-0.7% GAAP) and 1.4 million RSF of signed-not-occupied leases worth ~$69 million of annual rent begin landing around November, but leverage sits at 7.0x against a 5.6x–6.2x year-end target with only $170 million of a $2.90 billion disposition program closed. The 2026 outcome now hinges far more on the pace of asset sales into a market that has repeatedly repriced ARE's own non-core book downward than on anything happening inside the operating portfolio.

Guidance and trajectory

Management narrowed 2026 adjusted FFO per share guidance to $6.35–$6.45 from $6.30–$6.50, holding the $6.40 midpoint. The composition changed even though the midpoint did not: higher interest expense (+$20 million) and lower capitalized interest (-$5 million) are offset by the benefit of dispositions closing later than assumed. Other assumptions:

Q4 adjusted FFO per share guidance of $1.40–$1.50 was reiterated but management now expects to land "at the lower end" of it, on lower capitalized interest as project milestones are hit. The $10 million cut to straight-line rent revenue is a credit signal worth noting: it reflects "write-offs and reserves of deferred rent related to tenant wind-downs," with the full-year assumption of a $25–$30 million FFO hit from tenant wind-downs unchanged — about $14 million recognized in 1H26, $8 million of it in Q2. Roughly half that assumed damage is still ahead.

Our read. Simple arithmetic on the guidance: 1H26 adjusted FFO was $3.46, so the $6.40 midpoint requires $2.94 across 2H26 versus $3.46 in 1H26 — management is guiding to a further step down, with Q4 flagged toward the bottom of its range. Occupancy guidance of 86.2%–87.8% against 86.9% today embeds roughly a 1-point benefit from vacant assets management hopes to classify as held for sale; strip that and the operating portfolio is guided roughly flat to slightly lower on occupancy, with the signed-not-occupied backlog essentially offsetting the 451,450 RSF of known expirations.

Three things would change the trajectory, in order of importance. First, disposition execution — $2.73 billion of the $2.90 billion program is still unclosed, and both the leverage target and the interest-expense line depend on it; the market has already shown it will pay less than book for these assets. Second, whether Q2's -0.7% rollover rent holds or reverts toward Q1's -15%; one quarter is not a trend, and 1.4 million RSF of 2027 expirations with 12–24 months of expected downtime will test it. Third, whether tenant wind-downs stay inside the $25–$30 million assumption.

The floor under the equity is real — 9.7-year debt duration, 6% of debt maturing through 2028, $3.60 billion of liquidity, a dividend covered 2.4x — so this is a question of when earnings trough, not of solvency. On the filing's own numbers, that trough is not in this quarter's results: with guidance implying a weaker second half and impairments still being set by live buyer negotiations, the case for stabilization rests on 2027 deliveries and the signed-not-occupied backlog, neither of which shows up in reported FFO before late this year.

Source: Alexandria Real Estate Equities, Inc. Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 3, 2026.